|
01/19/2021
|
Summary ToggleEledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference
|
|
01/04/2021
|
Summary ToggleNovus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook
|
|
12/22/2020
|
Summary ToggleNovus Therapeutics Announces Results of Special Meeting of Stockholders
|
|
12/09/2020
|
Summary ToggleNovus Therapeutics Appoints June Lee, M.D., to Board of Directors
|
|
11/16/2020
|
Summary ToggleNovus Therapeutics Reports Third Quarter 2020 Financial Results
|
|
11/10/2020
|
Summary ToggleNovus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16
|
|
11/02/2020
|
Summary ToggleNovus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
|
|
10/02/2020
|
Summary ToggleNovus Therapeutics Announces One-for-Eighteen Reverse Stock Split
|
|
09/15/2020
|
Summary ToggleNovus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
|
|
09/14/2020
|
Summary ToggleNovus Therapeutics Announces Acquisition of Anelixis Therapeutics
|
